Bioverativ(BIVV) Adds a Fifth Director, Reports Additional Positive Long Term Data On ALPROLIX
Following its spin off from Biogen(BIIB) in January, Bioverativ(BIVV) had merely four Directors- CEO John Cox and three independent Directors. This represented an unusually small Board for a company with a market cap of over $5 billion, and it was probably inevitable that the Board would grow. Last week, Bioverativ added a fifth director, Anna Protopapas. Ms. Protopapas… Read More »